Intended Use
AlcoChange is a Digital therapeutic intended to reduce alcohol use and maintain abstinence in individuals with established alcohol-related liver disease (ArLD)
Indications for Use
AlcoChange is intended to increase abstinence and reduce alcohol use in patients with alcohol related liver diseases (ARLD) by providing behavioural therapy based on CyberLiver Behaviour Change (CBC) Model that is designed from a blend of principles from various behaviour change theories in the design of Digital Behaviour Change Techniques (DBCTs), Digital Behaviour Change Interventions (DBCI’s) and Personalised Behaviour Change Notifications (BCN’s). AlcoChange is intended to provide behavioural therapy as an adjunct to a contingency management system, for patients 18 years of age and older who are currently enrolled in outpatient treatment under the supervision of a clinician. AlcoChange is indicated as a 12-week prescription-only treatment for patients with Alcohol Related Liver Disease.
Users
- Patients
- Healthcare Professionals
- Trained Operators
How Users access the Device
Patients
Patients using the prescription code complete a registration/sign-up procedure as part of the onboarding process.
Healthcare Professionals / Trained Operators
Healthcare Professionals / Trained Operators need to be fully trained in the use of the software application.
Please refer this link for Instructions of use